Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Current Cardiology Reports

• Publication date

  2016-04-23

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11886-016-0730-0PMID 27108362
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.

  2016cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Resveratrol, a red wine antioxidant, reduces atrial fibrillation susceptibility in the failing heart by PI3K/AKT/eNOS signaling pathway activation.

  2015cited by this paper
• Relation between cancer and atrial fibrillation (from the REasons for Geographic And Racial Differences in Stroke Study).

  2015cited by this paper
• Radiotherapy-Induced Malfunction in Contemporary Cardiovascular Implantable Electronic Devices: Clinical Incidence and Predictors.

  2015cited by this paper
• Management of patients with implantable cardioverter-defibrillators and pacemakers who require radiation therapy.

  2015cited by this paper
• Arrhythmias in the Setting of Hematopoietic Cell Transplants

  2015cited by this paper
• Cancer Chemotherapy and Cardiac Arrhythmias: A Review

  2015cited by this paper
• QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review

  2015cited by this paper
• Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

  2015cited by this paper
• QT Prolongation and Oncology Drug Development.

  2015cited by this paper
• Treatment approach, delivery, and follow-up evaluation for cardiac rhythm disease management patients receiving radiation therapy: retrospective physician surveys including chart reviews at numerous centers.

  2014cited by this paper
• Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

  2014cited by this paper
• A national audit of current cardiac device policies from radiotherapy centres across the UK.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

  2014cited by this paper
• Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

  2014cited by this paper
• Insights into onco-cardiology: atrial fibrillation in cancer.

  2014cited by this paper
• Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide.

  2014cited by this paper
• Colchicine suppresses atrial fibrillation in failing heart.

  2014cited by this paper
• Malfunctions of implantable cardiac devices in patients receiving proton beam therapy: incidence and predictors.

  2013cited by this paper
• Incidence of supraventricular arrhythmias during autologous peripheral blood stem cell transplantation.

  2013cited by this paper
• 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

  2013cited by this paper
• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013cited by this paper
• 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

  2013cited by this paper
• Cardiovascular Safety of Tyrosine Kinase Inhibitors: With a Special Focus on Cardiac Repolarisation (QT Interval)

  2013cited by this paper
• High incidence of implantable cardioverter defibrillator malfunctions during radiation therapy: neutrons as a probable cause of soft errors.

  2013cited by this paper
• Cardiotoxicity Associated with the Tyrosine Kinase Inhibitor Sunitinib

  2013cited by this paper
• Superior vena cava defibrillator coils make transvenous lead extraction more challenging and riskier.

  2013cited by this paper
• Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.

  2013cited by this paper
• Incidence and Risk of QTc Interval Prolongation among Cancer Patients Treated with Vandetanib: A Systematic Review and Meta-analysis

  2012cited by this paper
• Management of radiation oncology patients with a pacemaker or ICD: A new comprehensive practical guideline in The Netherlands

  2012cited by this paper
• Colorectal cancer and risk of atrial fibrillation and flutter: a population-based case–control study

  2012cited by this paper
• Suppression of Phosphoinositide 3-Kinase Signaling and Alteration of Multiple Ion Currents in Drug-Induced Long QT Syndrome

  2012cited by this paper
• Atrial fibrillation following autologous stem cell transplantation in patients with multiple myeloma: incidence and risk factors

  2012cited by this paper
• Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs.

  2012cited by this paper
• Effect of radiation therapy on permanent pacemaker and implantable cardioverter-defibrillator function.

  2012cited by this paper
• Optimization of the in vitro cardiac safety of hydroxamate-based histone deacetylase inhibitors.

  2011cited by this paper
• Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.

  2011cited by this paper
• The 11th World Survey of Cardiac Pacing and Implantable Cardioverter‐Defibrillators: Calendar Year 2009–A World Society of Arrhythmia's Project

  2011cited by this paper
• The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with

  2011cited by this paper
• [Pacemaker, implanted cardiac defibrillator and irradiation: Management proposal in 2010 depending on the type of cardiac stimulator and prognosis and location of cancer].

  2011cited by this paper
• Melphalan‐Induced Supraventricular Tachycardia: Incidence and Risk Factors

  2011cited by this paper
• CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.

  2011cited by this paper
• Pacemaker, défibrillateur et radiothérapie : propositions de conduite à tenir en 2010 en fonction du type de stimulateur cardiaque, du pronostic et du site du cancer

  2011cited by this paper
• Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database.

  2010cited by this paper
• Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in malignancy.

  2010cited by this paper
• Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Cardiac complications in patients undergoing a reduced-intensity conditioning hematopoietic stem cell transplantation

  2010cited by this paper
• Cardiotoxicity of tyrosine kinase inhibitors in chronic myelogenous leukemia therapy

  2009cited by this paper
• Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.

  2009cited by this paper
• AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the

  2009cited by this paper
• AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the

  2009cited by this paper
• Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation.

  2009cited by this paper
• Radiation therapy in oncology patients who have a pacemaker or implantable cardioverter-defibrillator

  2009cited by this paper
• Life-Threatening Pacemaker Dysfunction Associated With Therapeutic Radiation: A Case Report

  2009cited by this paper
• QTc prolongation assessment in anticancer drug development: clinical and methodological issues

  2009cited by this paper
• Introducing a new entity: chemotherapy-induced arrhythmia.

  2009cited by this paper
• ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker

  2008cited by this paper
• Effects of Scatter Radiation on ICD and CRT Function

  2008cited by this paper
• Drug-induced QTc interval prolongation: a proposal towards an efficient and safe anticancer drug development.

  2008cited by this paper
• Age and gender trends in implantable cardioverter defibrillator utilization: A population based study

  2008cited by this paper
• A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer

  2008cited by this paper
• ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker

  2008cited by this paper
• Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia.

  2008cited by this paper
• First diagnosis of colorectal or breast cancer and prevalence of atrial fibrillation

  2008cited by this paper
• Molecularly targeted oncology therapeutics and prolongation of the QT interval.

  2007cited by this paper
• Early and Late Arrhythmogenic Effects of Doxorubicin

  2007cited by this paper
• Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.

  2007cited by this paper
• Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.

  2007cited by this paper
• Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.

  2006cited by this paper
• Interference detection in implantable defibrillators induced by therapeutic radiation therapy.

  2006cited by this paper
• Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma

  2006cited by this paper
• A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

  2006cited by this paper
• Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.

  2006cited by this paper
• Inaccurate electrocardiographic interpretation of long QT: the majority of physicians cannot recognize a long QT when they see one.

  2005cited by this paper
• Influence of radiotherapy on the latest generation of implantable cardioverter-defibrillators.

  2005cited by this paper
• Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade.

  2005cited by this paper
• Influence of radiotherapy on the latest generation of pacemakers.

  2005cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• Treatment of patients with cardiac pacemakers and implantable cardioverter-defibrillators during radiotherapy.

  2004cited by this paper
• Inflammation as a Risk Factor for Atrial Fibrillation

  2003cited by this paper
• Mechanisms of Clinical Arrhythmias

  2003cited by this paper
• Effect of arsenic trioxide on QT interval in patients with advanced malignancies.

  2003cited by this paper
• Esmolol is antiarrhythmic in doxorubicin‐induced arrhythmia in cultured cardiomyocytes – determination by novel rapid cardiomyocyte assay

  2003cited by this paper
• Influence of high-energy photon beam irradiation on pacemaker operation.

  2002cited by this paper
• Cardiac toxicity of arsenic trioxide.

  2001cited by this paper
• United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

  2001cited by this paper
• Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation

  2001cited by this paper
• Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

  2001cited by this paper
• The cardiac pacemaker patient--might the pacer be directly irradiated?

  2000cited by this paper
• Complete Remission after Treatment of Acute Promuelocytic Leukemia with Arsenic Trioxide

  1999cited by this paper
• Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.

  1999cited by this paper
• Syk and Bruton's Tyrosine Kinase Are Required for B Cell Antigen Receptor-mediated Activation of the Kinase Akt*

  1999cited by this paper
• Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients.

  1997cited by this paper
• Management of radiation oncology patients with implanted cardiac pacemakers: report of AAPM Task Group No. 34. American Association of Physicists in Medicine.

  1994cited by this paper
• Management of Radiation Oncology Patients with Implanted Cardiac Pacemakers

  1994cited by this paper
• Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study.

  1992cited by this paper
• An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy.

  1992cited by this paper

• Chemo-/radiotherapy-induced cardiomyopathy: roles of mitochondria and endoplasmic reticulum

  2025cites this paper
• A review of cardioprotective effect of ginsenosides in chemotherapy-induced cardiotoxicity

  2024cites this paper
• Special Populations in Ambulatory Surgery: Oncologic, Lactating, Transgender and Gender Diverse, and Suicidal Ideation

  2024cites this paper
• Use of new and emerging cancer drugs: what the cardiologist needs to know.

  2024cites this paper
• Seasonal variations of arrhythmias and their impact on mortality in cancer patients with health disparities: A propensity score adjusted machine learning analysis of over 100 million hospitalizations across 3 years

  2024cites this paper
• Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology

  2024cites this paper
• Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

  2023cites this paper
• Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study

  2023cites this paper
• Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.

  2023cites this paper
• Protection against cancer therapy-induced cardiovascular injury by planed-derived polyphenols and nanomaterials.

  2023cites this paper
• Cardiac Injury Following Chemo/Radiation Therapy: An Updated Review on Mechanisms and Therapeutic Approaches.

  2023cites this paper
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022cites this paper
• 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS).

  2022cites this paper
• ANMCO POSITION PAPER: cardio-oncology in the COVID era (CO and CO)

  2021cites this paper
• New-Onset Cancer in the HF Population: Epidemiology, Pathophysiology, and Clinical Management

  2021cites this paper
• QT prolongation and cancer therapeutics: a coming Tempest or Much Ado About Nothing?

  2021cites this paper
• Cancer Risk in the Heart Failure Population: Epidemiology, Mechanisms, and Clinical Implications

  2020cites this paper
• Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations.

  2020cites this paper
• Emerging Challenges of Radiation-Associated Cardiovascular Dysfunction (RACVD) in Modern Radiation Oncology: Clinical Practice, Bench Investigation, and Multidisciplinary Care

  2020cites this paper
• Interventional Cardiology in the Cancer Patient

  2019cites this paper
• Electrophysiologic Complications in Cancer Patients.

  2019cites this paper
• Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities.

  2019cites this paper
• QT Interval Prolongation Associated With Cytotoxic and Targeted Cancer Therapeutics

  2019cites this paper
• Arrhythmogenic Anticancer Drugs in Cardio-Oncology.

  2019cites this paper
• Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge

  2018cites this paper
• Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1

  2018cites this paper
• Cardio-oncology: a new and developing sector of research and therapy in the field of cardiology

  2018cites this paper
• Patterns of on-treatment cardiac adverse events within three clinical trials of adjuvant anthracycline-based chemotherapy

  2018cites this paper
• Electrophysiologic Toxicity of Chemoradiation

  2018cites this paper
• Cancer, atrial fibrillation, and stroke.

  2017cites this paper
• Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies

  2017cites this paper
• Cardio-Oncology – A new subspecialty with collaboration at its heart

  2017cites this paper
• Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

  2017cites this paper
• Radiotherapy for Patients with Cardiovascular Implantable Electronic Devices: A Review.

  2017cites this paper
• Arrhythmia prevention and device management: Before cancer therapy

  year unknowncites this paper